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ized by hyperferritinemia, normal transferrin saturation, and iron
overload in macrophages. A non-classical form is characterized by
additional hepatocellular iron deposits and a high transferrin sat-
uration. Both forms demonstrate autosomal dominant transmis-
sion and are associated with ferroportin gene (SLC40A1)
mutations. SLC40A1 encodes a cellular iron exporter expressed
in macrophages, enterocytes, and hepatocytes. The aim of the
analysis is to determine the penetrance of SLC40A1 mutations
and to evaluate in silico tools to predict the functional impair-
ment of ferroportin mutations as an alternative to in vitro studies.
Methods:We conducted a systematic review of the literature and
meta-analysis of the biochemical presentation, genetics, and
pathology of ferroportin disease.
Results: Of the 176 individuals reported with SLC40A1mutations,
80 were classiﬁed as classical phenotype with hyperferritinemia
and normal transferrin saturation. The non-classical phenotype
with hyperferritinemia and elevated transferrin saturation was
present in 53 patients. The remaining patients had normal serum
ferritin or the data were reported incompletely. Despite an
increased hepatic iron concentration in all biopsied patients, sig-
niﬁcant ﬁbrosis or cirrhosis was present in only 11%. Hyperferr-
itinemia was present in 86% of individuals with ferroportin
mutations. Bio-informatic analysis of ferroportin mutations
showed that the PolyPhen score has a sensitivity of 99% and a
speciﬁcity of 67% for the discrimination between ferroportin
mutations and polymorphisms.Journal of Hepatology 20
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load of hepatic iron.
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Ferroportin disease is a clinically and genetically heterogeneous
iron overload syndrome [1]. Its clinical presentation has been
documented in individual case reports and small case series. The
natural course has been reported in one small series [2]. Hyper-
ferritinemia, a normal to low transferrin saturation and Kupffer
cell iron storage, presenting as hepatic and spleen iron overload,
are considered characteristic features of classical ferroportin dis-
ease [3]. Increased transferrin saturation and hepatocellular iron
overload, in addition to hyperferritinemia and macrophage iron
loading, is considered characteristic for the non-classical pheno-
type [3,4].
A genotype–phenotype correlation was suggested to explain
the clinical heterogeneity of the disease where most mutations
(e.g. A77D, D157G, V162del, N174I, Q182H, Q248H, and G323V)
are associated with classical ferroportin disease [5–8]. Distinct
mutations (e.g. N144H, Y64N, C326Y/S, S338R, Y501C) have been
found in patients who presented with the non-classical phenotype
[5,9–12].
Ferroportin is the only knownmammalian iron exporter and is
expressed in macrophages and the basolateral membrane of
enterocytes and hepatocytes [13–15]. In classical ferroportin dis-
ease, macrophage iron overload results from cellular iron export
deﬁciency, i.e. loss of ferroportin function [6]. TheD157Gmutation
leads to hepcidin-independent, constitutive binding of Janus
Kinase 2 (JAK2) and thus triggers ferroportin down-regulation
[16]. The concept that other loss of functionmutations of ferropor-
tin result in intracellular retention of the iron export pump has
been challenged recently [17,18], but alternative mechanisms
leading to iron transport deﬁciency have not been fully elucidated.
Ferroportin inactivation is mediated by the peptide hormone
hepcidin [19,20]. Distinct mutations render ferroportin resistant10 vol. 53 j 941–949
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to inactivation by hepcidin and cause a gain of iron export func-
tion, which results in hyper-absorption of dietary iron.
Hepcidin is secreted by hepatocytes into the circulation in
response to pro-inﬂammatory cytokines, hepatocellular iron
loading, and endoplasmic reticulum stress [21,22]. Circulating
hepcidin directly interacts with ferroportin and induces its inter-
nalization and degradation [23]. The free thiol group of cysteine
326 of ferroportin is essential for hepcidin binding and ferropor-
tin gene mutations affecting residue 326 result in hepcidin resis-
tance [7,24]. Patients with ferroportin disease due to hepcidin
resistance mutations, exhibit a non-classical phenotype [8,25,26].
Functional studies in cells overexpressing ferroportin variants
have been used to differentiate between gain-of-function and
loss-of-function mutations and benign sequence variants. The
functional relevance of ferroportin mutations can also be deduced
from mutation segregation studies within families with ferropor-
tin disease. Association studies of SLC40A1 polymorphisms with
serum iron indices in population studies indirectly provide
evidence for their functional relevance [27–29].
Bio-informatic tools were used to complement the genetic
and functional studies. SIFT [30] and PolyPhen [31] provide an
in silico prediction of the functional consequences of missense
mutations. The use of these tools in differentiating between dis-
eases-associated ferroportin mutations from benign sequence
variants was assessed. The clinical presentation and penetrance
of ferroportin gene mutations were assessed from a systematic
review of the literature.
Methods
Search strategy
A systematic literature search was undertaken in Medline from 1996 to June 2009
according to the following search strategy: #1 (‘SLC40A1’ or ‘SLC11A3’ or ‘ferro-
portin’ or ‘IREG’ or ‘IREG1’ or ‘IREG-1’ or ‘ferroportin’ or ‘ferroportin1’ or ‘ferropor-
tin-1’ or ‘FPN’ or ‘FPN1’ or ‘FPN-1’).mp. [mp = title, original title, abstract, name of
substance word, subject heading word]; #2 (‘mutation’ or ‘variant’).mp. [mp = ti-
tle, original title, abstract, name of substance word, subject heading word]; # 3:
#1 and #2. This search retrieved 143 references and was supplemented by man-
ual searching for references of the relevant articles identiﬁed. After exclusion of
review articles and non-human studies, data from 49 studies were included. This
search was complemented by an Embase search using the search strategy: #1
(?SLC40A1? or ?SLC11A3? or ?ferroportin? or ?IREG? or ?IREG1? or ?IREG-1? or
?ferroportin? or ?ferroportin1? or ?ferroportin-1? or ?FPN? or ?FPN1? or ?FPN-
1?).mp. [mp = title, original title, abstract, name of substance word, subject head-
ing word]; #2 (?mutation? or ?variant?).mp. [mp = title, original title, abstract,
name of substance word, subject heading word]; # 3: #1 and #2.
Prediction of the functional effect of amino acid substitutions by in silico analysis
Two algorithms were used to evaluate the impact of amino acid substitutions on
the function of ferroportin: polymorphism phenotyping (PolyPhen) [31–33] and
sorting intolerant from tolerant (SIFT) [30]. Genetic variants of SLC40A1, identi-
ﬁed in patients with suspected iron overload, were collected from the systematic
review of the literature. In addition, single nucleotide polymorphisms of SLC40A1
were collected from the literature and from ENSEMBL (http://www.ensembl.org/)
and the NCBI databases (http://www.ncbi.nlm.nih.gov/). A SLC40A1 variant was
considered a mutation in case its frequency in the control population was unde-
termined, or lower than 1:50, and the variant was not reported in a SNP database
[27–29,34,35].
PolyPhen
PolyPhen (= Polymorphism Phenotyping) is an automatic tool for prediction of
possible impact of an amino acid substitution on the structure and function of
a human protein. The predictive value of the PolyPhen score was demonstrated
in diabetes mellitus [36] and cancer genetics [37]. This prediction is based on942 Journal of Hepatology 201empirical rules which are applied to the sequence, phylogenetic, and structural
information characterizing the substitution [31]. PolyPhen was employed, as
available at http://coot.embl.de/PolyPhen/ (version August 12, 2008), using the
NCBI protein accession number Q9NP59 (SLC40A1) for ferroportin. In all cases,
the prediction basis was only the default position-speciﬁc independent counts
(PSIC) score derived from multiple sequence alignment of observations. PolyPhen
scores of >2.0 indicated protein function as ‘probably damaging’ and scores of
<1.5 as ‘benign’. A PolyPhen score of 1.5–2.0 is classiﬁed as ‘possibly’ damaging.
A phylogenetic sequence alignment of selected ferroportin protein sequences
is shown in Fig. 2.
SIFT
SIFT (= Sorting Intolerant from Tolerant) is a sequence-homology-based tool that
presumes that important amino acids will be conserved in the protein family.
Changes at well-conserved positions tend to be predicted as deleterious. SIFT is
a multi-step procedure that uses multiple alignment information to predict toler-
ated and deleterious substitutions for every position of the query sequence [30].
The SIFT Blink algorithm was applied to compare amino acid sequences of differ-
ent organisms chosen from precomputed NCBI BLAST searches. For query in SIFT
Blink, GI: 49065554 (SLC40A1) was used to analyze the protein sequence by using
the parameter ‘best BLAST hit to each organism’ and omitting sequences >90%
identical to query. Edited alignments were reanalyzed by the appropriate module
of SIFT (http://blocks.fhcrc.org/sift/SIFT_aligned_seqs_submit.html). Results were
reported as ‘affects protein function’ or ‘tolerated’ according to this analysis.
To evaluate the bio-informatic tools to distinguish between benign and dis-
ease sequence variants, the SLC40A1 polymorphisms were used as true negatives
and genetic variants of SLC40A1 identiﬁed in patients with ferroportin disease as
true positives. The PolyPhen and SIFT scores were then analyzed in a ROC curve
for their sensitivity and speciﬁcity.
Statistical analysis
For statistical analysis the software package for social sciences (SPSS v15.0) was
used. To test for correlation between parameters, Pearson correlation was carried
out for normally distributed parameters and Spearman rank correlation for non-
normally distributed parameters. Normality of distribution was tested by Kol-
mogorov–Smirnov curve-ﬁtting. Differences between groups were analyzed by
Kruskal Wallis test for non-Gaussian distributed variables. Correlations and dif-
ferences were considered signiﬁcant if p <0.05. Sensitivity and speciﬁcity of SIFT
and PolyPhen scores were calculated form the ROC curve analysis using muta-
tions identiﬁed in patients with ferroportin disease as true positives and poly-
morphisms reported in the SNP database (http://www.ncbi.nlm.nih.gov/sites/
entrez) as true negatives.Results
High biochemical penetrance and variable clinical presentation of
SLC40A1 mutations
One hundred and seventy-six individuals with ferroportin gene
mutations were reported in the literature, and their demographic
and biochemical data are listed in Table 1. The diagnosis of ferro-
portin disease was most frequently made in the 3rd to 4th decade
of life and 43% of patients were female.
To describe the disease presentation and the penetrance of
underlying mutations, serum iron parameters, liver biopsy ﬁnd-
ings, MRI, comorbidities, and phlebotomy status were assessed.
These were reported incompletely for several patients (Table 1).
Forty-ﬁve comorbidities were reported in 29 patients (viral
hepatitis 3, steatosis 12, obesity 5, diabetes 8, impaired glucose
tolerance 2, hyperlipidemia 2, increased alcohol consumption 2,
and sarcoidosis 2). Mean age and mean serum ferritin were sig-
niﬁcantly higher in patients with comorbidities, than in patients
without comorbidities, (52 ± 15 years vs. 39 ± 20 years p = 0.002
and 3133 ± 3270 lg/L vs. 1965 ± 2067 lg/L, p = 0.017). Fibrosis
PF1 (Metavir) was signiﬁcantly more common in patients with0 vol. 53 j 941–949
Fig. 1. Genotype to phenotype correlation of ferroportin disease: patients
with ferroportin disease identiﬁed from the systematic meta-analysis were
grouped according to the SLC40A1 mutation. Box-Whisker blots of (A) serum
ferritin, and (B) transferrin saturation in mutations reported in more than 5
patients are shown. Boxes represent 25th and 75th percentile, Whiskers range
and horizontal lines represent the median. Outliers are shown as circles. Grey,
dark blue, and light blue boxes indicate that all patients reported with the
respective mutation were classiﬁed as classical, non-classical, or variable bio-
chemical phenotype, respectively, i.e. all patients had low or normal transferrin
saturation (grey), increased transferrin saturation (dark blue), or different
patients with the same mutation had variable transferrin saturation (light blue).
Any outliers are marked with a circle and extreme cases with an asteriks.
JOURNAL OF HEPATOLOGYcomorbidities than in patients without comorbidities (12 of 44
vs. 10 of 18; Fisher’s exact test p <0.05).
The biochemical penetrance of ferroportin disease was 86%
(142 of 166 patients), deﬁned as hyperferritinemia >300 lg/L in
males and >200 lg/L in females. We found a signiﬁcant correla-
tion between serum ferritin and age (r2 = 0.344, n = 158,
p <0.001). The phenotype of hyperferritinemic patients was clas-
siﬁed as classical if transferrin saturation was normal and as non-
classical if transferrin saturation was increased (males >50%,
females >45%). Classical disease was present in 80 patients asJournal of Hepatology 201opposed to 53 patients with non-classical disease, whose mean
age at presentation was signiﬁcantly higher (44 vs. 37 years,
p <0.05) (Table 2). Serum iron parameters for the remaining 43
patients were either incompletely reported or normal (16
patients). Differences between classical and non-classical pheno-
type are evident in Table 2 where mean hemoglobin, ferritin,
and hepatic iron concentration (HIC) were signiﬁcantly lower in
the classical disease cohort.
Liver iron was increased in 30 of 31 reported patients, with
a mean HIC of 310 lmol/g (normal <25 lmol/g) [38]. Liver
ﬁbrosis PF2 or liver cirrhosis was present in 7 of 53 biopsied
patients (13%), and correlated with age (mean 53.3 vs.
36.2 years, p <0.001). Cirrhosis was reported in 4 of 176
patients, of whom 2 had the N144H mutation, one patient the
C326S and one the I180T mutation [25,39,40]. One patient with
ferroportin disease was diagnosed with hepatocellular carci-
noma which was possibly linked with occult hepatitis B virus
infection [2].
In search of factors that discriminate ferroportin disease
severity, the correlation between patient demographics, serum
iron parameters, and liver biopsy ﬁndings was determined. The
stage of liver ﬁbrosis correlated signiﬁcantly with age (r = 0.54,
n = 53, p <0.001), but neither with HIC nor with serum ferritin.
HIC and transferrin saturation (r = 0.528, p = 0.003, n = 29), and
HIC and serum ferritin (r = 0.423, p = 0.018, n = 31) showed a
moderate correlation.Genotype–phenotype correlation partly explains variability in
clinical presentation
Of 31 SLC40A1 mutations, 6 and 5 were unequivocally associated
with the classical or the non-classical phenotype, respectively
(Table 2). Variablephenotypes in individual patientswith the same
mutation were reported for 9 mutations (Fig. 1 and Table 3).
MRI ﬁndings of liver and spleen iron were reported for 8 fer-
roportin mutations (c.-188A>G, G490D, I152F, L233P, R178G,
V162del, Y64 N, Y501C) [12,41–45,5,46] where the small number
of patients prohibits assessment of the diagnostic performance of
MRI for the classiﬁcation of ferroportin disease.How to differentiate between SLC40A1 mutations and
polymorphisms
Ferroportin disease is genetically heterogeneous with 36 differ-
ent SLC40A1 mutations reported [8–10,12,26–29,38–41,45–68]
as summarized in Table 3. In addition, 9 ferroportin gene poly-
morphisms were reported, 3 of which were associated with
increased serum ferritin in various populations (Table 4)
[29,34]. The allele frequencies of 29 disease-associated ferropor-
tin mutations had been determined in matched populations and
was found to be <1:100. It remains unclear whether L233V and
D270P, each of which have been identiﬁed in single patients with
iron overload, are disease-causing mutations or represent benign
sequence variants [43,65].
To determine whether bio-informatic tools PolyPhen and SIFT
[30,32,69] can discriminate between disease-causing SLC40A1
mutations and benign sequence variants, their ability to classify
known ferroportin sequence variants accordingly was tested.
The predicted functional impairment of individual sequence
variants from the PolyPhen and SIFT tools were used as outcome0 vol. 53 j 941–949 943
Fig. 2. Phylogenetic alignment of ferroportin protein sequences of various species: Disease-associated ferroportin gene mutations are highlighted in light blue.
Single nucleotide polymorphisms are shown in dark blue.
Research Articlevariables for a receiver-operator curve analysis. The PolyPhen
score had a high diagnostic accuracy with a calculated area under
the ROC curve (AUROC) of 0.798 (p = 0.014) (Fig. 3). Using the
descriptive output of PolyPhen (i.e. probably damaging, possibly
damaging or benign) as predictors of the functional consequence
of particular gene variants, the sensitivity of the PolyPhen score
was 99% and the speciﬁcity 67% (Table 2 and Fig. 3). SIFT analysis
predicted that 23 of 32 disease associated missense mutations
‘affects’ protein function and 9 are ‘tolerated’. Of 9 reported poly-
morphisms 7 were classiﬁed as ‘tolerated’ (AUROC 0.605
p = 0.37). The bio-informatics PolyPhen tool has a higher sensitiv-
ity and speciﬁcity than the SIFT score for the discrimination
between missense mutations and single nucleotide polymor-
phisms of SLC40A1.
Serum ferritin concentration (r = 0.226, n = 136, p = 0.008),
and transferrin saturation (r = 0.198, n = 128, p = 0.025) were
correlated with the PolyPhen score, suggesting that ferroportin944 Journal of Hepatology 201disease is more severe when phylogenetically more conserved
residues are affected by the mutation.Discussion
Ferroportin disease is the commonest genetic iron overload syn-
drome after HFE associated hemochromatosis and has a variable
clinical presentation. This review of the literature and meta-anal-
ysis shows that hyperferritinemia and increased hepatic iron con-
centration are characteristic signs of the disease. In contrast,
elevated transferrin saturation and splenic iron overload are var-
iably present. Hyperferritinemia was found in 86% of individual
with ferroportin mutations, but incomplete reporting is a limita-
tion for the accurate assessment of disease penetrance. The
observed correlation between age and serum ferritin supports
the concept that ferroportin disease is a progressive iron overload0 vol. 53 j 941–949
Table 1. Summary of demographics and clinical characteristics of 176 patients
with ferroportin disease. (Note not all parameters were reported for each
patient.)
*Phlebotomy was reported for 82 patients. Grams iron removed was reported for
20 patients.
Table 2. Characteristics of classical vs. non-classical phenotype of ferroportin
disease as deﬁned by the presence of hyperferritinemia with normal
transferrin saturation (classical) versus patients with hyperferritinemia and
elevated transferrin saturation (non-classical). Data are shown as
means ± standard deviation. Differences were tested for signiﬁcance using
student’s t-test.
JOURNAL OF HEPATOLOGYdisorder. It is therefore possible that patients detected through
cross-sectional study designs have not yet had time to develop
the ‘full-blown’ disease. Hence, it is difﬁcult to assess the true
penetrance without further follow-up data. By comparison, in
genetic hemochromatosis hyperferritinemia was present in 55–
86% of C282Y homozygotes [70,71] and cirrhosis was present inJournal of Hepatology 20136% of more severely affected C282Y homozygous individuals
with ferritin >1000 lg/L [72].
To assess the pathology of ferroportin disease, the ﬁndings of
liver biopsies were reviewed. However, liver biopsies were per-
formed in only a few patients and the results were inconsistently
reported. This prohibits a systematic classiﬁcation of ferroportin
disease based on liver biopsy results. In patients who underwent
liver biopsies for ferroportin disease, hepatic iron concentration
was invariably increased and the penetrance of liver ﬁbrosis
PF2 was 13%. Age, hepatic iron concentration, and comorbidities
were associated with ﬁbrosis stage and are thus potential risk
factors for ﬁbrosis in ferroportin disease.
A simple biochemical classiﬁcation strategy based on trans-
ferrin saturation was used as an alternative to liver biopsy.
Transferrin saturation is low to normal in classical ferroportin
disease and increased in patients with the non-classical pheno-
type. An arbitrary threshold for transferrin saturation of 45%
for females and 50% for males was used to distinguish classical
from the non-classical phenotype. The value of this simple classi-
ﬁcation is supported by our meta-analysis, which shows that
patients with the classical phenotype have lower hemoglobin
concentrations. This may explain why patients with classical fer-
roportin disease appear to tolerate therapeutic venesection less
well than hemochromatosis patients. MRI was proposed as an
alternative to liver biopsy to discriminate between classical and
non-classical ferroportin disease. However, no correlation
between parameters of disease severity and MRI ﬁndings has
been reported [73].
The genotype to phenotype correlation suggests that ferro-
portin disease has a multifactorial cause because not all muta-
tions were unambiguously correlated with the classical or non-
classical phenotype in all reported patients with a particular
mutation. Our meta-analysis suggests that Y64N, V72F, and
Y501C confer hepcidin resistance because the phenotypic pre-
sentation as non-classical disease is similar to the C326Y muta-
tion [7,74,75]. Similarly, classical mutations D157N, D181V,
G80V, Q182H, R489K, and V162del may impair the iron export
function of ferroportin through incorrect folding, subcellular
mislocalization, or direct inhibition of the iron transport func-
tion [6,18,75].
We have assessed PolyPhen and SIFT [76] as alternatives to pre-
dict the effect of ferroportin mutations on protein function,
because functional studies of ferroportin mutants [6,17,18,68,75]
have shown conﬂicting results [17,18]. Our analysis shows that
PolyPhen is a sensitive tool to identify disease-causing gene vari-
ants by classifyingmutations identiﬁed in patients with iron over-
load as ‘possibly’ or ‘probably’ damaging. The sensitivity of the
PolyPhen score is 99% and the speciﬁcity 67%. These ﬁndings sug-
gest that the functional effect of ferroportin mutations can be pre-
dicted in silico and that these tools may help to interpret the
relevance of newly-identiﬁed mutations in the future.
The systematic review of the molecular genetics and the
clinical presentation of ferroportin disease highlights the het-
erogeneity of the disease and the difﬁculties in securing the
diagnosis. Similar to HFE hemochromatatosis, age, and comor-
bidities appear to be important risk factors for the develop-
ment of ﬁbrosis in patients with ferroportin disease [77].
PolyPhen helps to score newly-identiﬁed, presumed SLC40A1
mutations; identiﬁcation of a genetic variant in SLC40A1 is
not sufﬁcient to conﬁrm ferroportin disease in patients with
hyperferritinemia.0 vol. 53 j 941–949 945
Table 3. Molecular genetics of SLC40A1mutations. The frequency of mutations highlighted with * in the control population can be inferred from studies, in which control
populations have been screened for the presence of another mutation, affecting the same residue.
**Predicted G468S.
Research Article
946 Journal of Hepatology 2010 vol. 53 j 941–949
Table 4. SLC40A1 non-synonymous single nucleotide polymorphisms. SNPs, which have been associated with high serum iron parameters are highlighted in bold and
italics.
aAs reported in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?chooseRs=coding&go=Go&locusId=30061).
bhttp://www.ensembl.org/Homo_sapiens/Variation/Summary?v=ENSSNP12180430;vdb=variation.
Fig. 3. Diagnostic performance analysis (ROC curve) of PolyPhen and SIFT
scores for the prediction of the functional consequence of ferroportin gene
variants. Genetic variants of SLC40A1 reported as polymorphisms were used as
true negatives and genetic variants of SLC40A1 identiﬁed in patients with
ferroportin disease were used as true positives. ROC curves are shown with the
sensitivity plotted along the abscissa, and 1 – speciﬁcity plotted along the
ordinate.
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